Response from Mr. Ehrlich to a question I asked below that ....
Hi David,
1. Remember we too don't know day to day results. At different timepoints in the trial Cellceutix will release information. I believe we have well updated all shareholders as to the present state of the trials.
2. Regarding p21, I cant yet give a time when they will run the new samples.
3. Releasing data on the trial before its conclusion is a difficult process but we do our best to update all our shareholders.
Best regards
Leo Ehrlich[/I]
On Mon, Oct 14, 2013 at 3:06 PM, David XXXXXXXX wrote:
Mr. Ehrlich,
I hope you and family are well. The PR last night was very exciting to read. It is mind boggling what you and Dr. Menon have accomplished since the PolyMedix acquisition and it appears “warp speed” has been initiated, ha-ha. Thanks for all the recent UPDATES. It just keeps getting better and better and honestly I’ve never had so much faith or confidence in the leadership or the pipeline of a developing Biopharmaceutical company….EVER. I’m eager to see how we fare at the Elsevier Therapeutic Area Partnerships conference in November but given your track record to date, I’m betting BIG on a WIN. I clearly now understand your comment on a former PR that stated “Looking back at the acquisition, we believe we have completed one of the most promising biotech acquisitions in recent years “…..no kidding….HOLY SHITOWSKI and I ain’t Polish. I have a few questions and I understand if you cannot address but if you can and do, I would like to share your response on Investors Hangout and XXXXXX message boards. My questions are below ( same subject ):
Given the fact ( or at minimum my understanding ) that Dana Farber understandably has influence/input as to when and what information ( as it relates to results, etc. ) on the Kevetrin trial can be released, will there be any updates on ANY positive or significant results on the recently completed Cohort 5 ?
Or the results of the DUPLICATED and MORE DEFINITIVE tests that were to be performed to confirm the p21 activation seen in 4 out of 5 patients at very low doses?
To net it out….. are you allowed to release ANY results prior to the end of the trial OR will ANY release of results or status be at the SOLE discretion of Dana Farber ?
Hi David,
1. Remember we too don't know day to day results. At different timepoints in the trial Cellceutix will release information. I believe we have well updated all shareholders as to the present state of the trials.
2. Regarding p21, I cant yet give a time when they will run the new samples.
3. Releasing data on the trial before its conclusion is a difficult process but we do our best to update all our shareholders.
Best regards
Leo Ehrlich[/I]
On Mon, Oct 14, 2013 at 3:06 PM, David XXXXXXXX wrote:
Mr. Ehrlich,
I hope you and family are well. The PR last night was very exciting to read. It is mind boggling what you and Dr. Menon have accomplished since the PolyMedix acquisition and it appears “warp speed” has been initiated, ha-ha. Thanks for all the recent UPDATES. It just keeps getting better and better and honestly I’ve never had so much faith or confidence in the leadership or the pipeline of a developing Biopharmaceutical company….EVER. I’m eager to see how we fare at the Elsevier Therapeutic Area Partnerships conference in November but given your track record to date, I’m betting BIG on a WIN. I clearly now understand your comment on a former PR that stated “Looking back at the acquisition, we believe we have completed one of the most promising biotech acquisitions in recent years “…..no kidding….HOLY SHITOWSKI and I ain’t Polish. I have a few questions and I understand if you cannot address but if you can and do, I would like to share your response on Investors Hangout and XXXXXX message boards. My questions are below ( same subject ):
Given the fact ( or at minimum my understanding ) that Dana Farber understandably has influence/input as to when and what information ( as it relates to results, etc. ) on the Kevetrin trial can be released, will there be any updates on ANY positive or significant results on the recently completed Cohort 5 ?
Or the results of the DUPLICATED and MORE DEFINITIVE tests that were to be performed to confirm the p21 activation seen in 4 out of 5 patients at very low doses?
To net it out….. are you allowed to release ANY results prior to the end of the trial OR will ANY release of results or status be at the SOLE discretion of Dana Farber ?
